Panitumumab CAPOX Dosing
The recommended dose of panitumumab when combined with CAPOX (capecitabine and oxaliplatin) is 6 mg/kg intravenously over 60 minutes on day 1, repeated every 2 weeks, though this specific combination is not formally established in major guidelines. 1, 2
Critical Context and Dosing Considerations
Standard Panitumumab Dosing with Oxaliplatin-Based Regimens
The established evidence supports panitumumab at 6 mg/kg IV over 60 minutes every 2 weeks when combined with FOLFOX (mFOLFOX6), not CAPOX specifically 1, 3. The CAPOX regimen itself uses:
- Oxaliplatin 130 mg/m² IV over 2 hours, day 1
- Capecitabine 850-1000 mg/m² PO twice daily for 14 days
- Repeated every 3 weeks 1
The Dosing Schedule Mismatch Problem
A critical caveat exists: CAPOX runs on a 3-week cycle, while panitumumab is dosed every 2 weeks. This creates a scheduling incompatibility that is not addressed in major guidelines. The NCCN guidelines 1 show CapeOX combined with bevacizumab (7.5 mg/kg every 3 weeks) but do not provide a panitumumab + CAPOX regimen.
Alternative Dosing Approaches Based on Available Evidence
Option 1 - Modified Schedule (Research-Based): Based on research evidence, a modified approach uses:
- Panitumumab 9 mg/kg IV every 3 weeks (to match CAPOX cycle)
- Oxaliplatin 130 mg/m² IV day 1
- Capecitabine 850-1000 mg/m² PO twice daily days 1-14
- Repeated every 3 weeks 4, 5
This 9 mg/kg every 3 weeks dosing was studied in a phase II trial 4 with acceptable toxicity, though it showed higher rates of grade 3-4 skin rash (19.2%) and diarrhea (18%).
Option 2 - Standard 2-Week Panitumumab with Modified CAPOX: Alternatively, maintain panitumumab at 6 mg/kg every 2 weeks and adjust the chemotherapy backbone to a 2-week cycle, though this deviates from standard CAPOX dosing.
Recommended Patient Selection Criteria
This regimen should only be used in:
- RAS wild-type (KRAS and NRAS exons 2,3,4) mCRC 3, 6
- BRAF wild-type tumors 6
- Left-sided primary tumors (splenic flexure to rectum) for optimal benefit 3, 6
- First-line metastatic setting 3
Geographic Dosing Considerations
North American patients may require lower capecitabine doses (850 mg/m² vs 1000 mg/m²) due to increased fluoropyrimidine toxicity compared to European patients 1. Start at 850 mg/m² with close first-cycle monitoring.
Safety Monitoring Requirements
Key toxicities to monitor:
- Skin toxicity (most common grade 3-4 adverse event with anti-EGFR therapy)
- Diarrhea (18-37% grade 3-4 with capecitabine combinations) 4, 7
- Oxaliplatin neuropathy (consider discontinuing after 3-4 months while continuing fluoropyrimidine + panitumumab) 1
- Hand-foot syndrome from capecitabine
Preferred Alternative Regimen
The better-established option is mFOLFOX6 + panitumumab 1, 3:
- Oxaliplatin 85 mg/m² IV day 1
- Leucovorin 400 mg/m² IV day 1
- 5-FU 400 mg/m² IV bolus day 1, then 1200 mg/m²/day × 2 days continuous infusion
- Panitumumab 6 mg/kg IV day 1
- Repeated every 2 weeks
This regimen has Level I, Grade A evidence from the PRIME and PEAK trials 3 and avoids the scheduling incompatibility issue.
Contraindications to Combined Anti-EGFR and Anti-VEGF Therapy
Never combine panitumumab with bevacizumab - this increases toxicity without improving outcomes 1.